A Phase 1 interventional study of Cabotegravir and Rifabutin in Infection, Human Immunodeficiency Virus and HIV Infections, sponsored by ViiV Healthcare. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-17.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing cabotegravir in HIV Infections — 4 open to participants now, 13 under way, 8 of them phase 3. cabotegravir · HIV Infections.
Among the 36 studies testing cabotegravir in HIV Infections, this one is the 33rd largest by enrollment, is one of 4 that started in 2017, is one of 10 in phase 1, and was the 13th registered.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
Browse HIV Infections studies →4 of the 36 studies testing cabotegravir in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in South Africa
Ages up to 10 days · Healthy volunteers
Africa Health Research Institute · Sites in South Africa
Ages 15–30 · Healthy volunteers
Evandro Chagas National Institute of Infectious Disease · Sites in Brazil
Ages 18–30 · Men only · Healthy volunteers
Duke University · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
cabotegravir: first FDA approval 2021 (VOCABRIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 11 · Phase 3 13 · Phase 4 3
First in 2008; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Median enrollment 200 across the 36 interventional studies. Of the 23 that completed or were terminated, 18 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 36 have an industry lead sponsor. The 7 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 197th largest by enrollment of the 210 interventional ones that give a count, is one of 10 that started in 2017, is one of 83 in phase 1, and was the 178th registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
1 of the studies testing cabotegravir in HIV Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06786520ViiV HealthcareA Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults | 2027-03-08 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing cabotegravir in HIV Infections, from their registry updates:
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
This is a Phase I, single-center, open-label, fixed-sequence, 2-period crossover study in healthy adults to evaluate the effect of oral rifabutin (RBT) 300 milligram (mg) on the pharmacokinetics of oral cabotegravir (CAB) 30 milligram ( mg). This study will evaluate the drug-drug interaction (DDI) potential between CAB and RBT to inform dosing strategies for tuberculosis in subjects receiving CAB for human immunodeficiency virus (HIV) treatment or prevention. In Treatment Period 1 (Treatment A) participants will receive CAB 30 mg once daily for 14 days, followed by Treatment Period 2 (Treatment B) where participants will receive RBT 300 mg once daily with CAB 30 mg once daily for 14 days. The total study duration will be approximately for 10 weeks. Approximately 15 healthy subjects will be enrolled to ensure that 12 subjects complete dosing and critical assessments.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
This study's enrollment of 15 is below the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Browse HIV Infections studies →ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
Compared within HIV Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A female subject is eligible to participate if she is not pregnant (as confirmed by a negative serum human chorionic gonadotrophin (hCG) test), not lactating, and if she is of:
The investigator is responsible for ensuring that subjects understand how to properly use these methods of .
Exclusion Criteria
History of cardiovascular disease including
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be administered a single oral dose of CAB 30 mg after an overnight fast of at least 6 hours for 14 days in Period 1. Dosing of study medication on non-PK days may be with or without food.
Drug: Cabotegravir
Participants will be administered a single dose of RBT 300 mg and a single dose of CAB 30 mg after an overnight fast of at least 6 hours once daily for 14 days in Period 2. Dosing of study medication on non-PK days may be with or without food.
Drug: Cabotegravir · Drug: Rifabutin
It will be available as a white aquarius film coated tablet for oral administration. CAB Tablet is composed of GSK1265744B (micronized) lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate
It will be available as an opaque red-brown hard gelatin capsules containing 150 mg of rifabutin for oral administration. These capsules are composed of rifabutin, microcrystalline cellulose, sodium lauryl sulphate, magnesium stearate, and silica gel
Assessment of Plasma CAB Pharmacokinetic (PK) Parameter: Area Under the Concentration-time Curve Over One Dosing Interval (AUC [0 to Tau])
Blood samples for PK analysis of CAB were collected at pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28. AUC (0 to tau) was calculated using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid. PK Summary Population included participants who had CAB PK parameter estimates from both serial PK sampling time periods 1 and 2. Comparisons were made for the repeated dose PK parameters of CAB when given alone in Period 1 and when co-administered with steady-state RBT in Period 2.
Time frame: Pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28
Assessment of Plasma CAB PK Parameter: Maximum Observed Concentration (Cmax)
Blood samples for PK analysis of CAB were collected at pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28. Cmax was determined directly from the concentration-time data. Comparisons were made for the repeated dose PK parameters of CAB when given alone in Period 1 and when co-administered with steady-state RBT in Period 2.
Time frame: Pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28
Assessment of Plasma CAB PK Parameter: Concentration at the End of the Dosing Interval (Ctau)
Blood samples for PK analysis of CAB were collected at pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28. Comparisons were made for the repeated dose PK parameters of CAB when given alone in Period 1 and when co-administered with steady-state RBT in Period 2.
Time frame: Pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28
Assessment of Plasma CAB PK Parameter: Time of Occurrence of Cmax (Tmax)
Blood samples for PK analysis of CAB were collected at pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28. Tmax was determined directly from the concentration-time data.
Time frame: Pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28
Assessment of Plasma CAB PK Parameter: Terminal Phase Half-life (t1/2)
Blood samples for PK analysis of CAB were collected at pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28. Apparent terminal half-life was calculated as: t1/2 = ln2 / Lambda_z, where Lambda_z is the terminal phase rate constant. Plasma t1/2 was not estimated for either period due to limited PK sampling in the terminal phase.
Time frame: Pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28
Assessment of Plasma CAB PK Parameter: The Apparent Oral Clearance (CL/F)
Blood samples for PK analysis of CAB were collected at pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28. CL/F was calculated as CL/F =Dose/AUC(0 to tau).
Time frame: Pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect and associated with liver injury and impaired liver function. Safety Population comprised of all participants who enrolled in the study and received at least one dose of study drug.
Time frame: Up to 10 weeks
Concurrent Medication Assessment in Treatment Period 1 and 2
Concurrent medications included paracetamol and ibuprofen. Number of participants who took concurrent medications during the study are presented.
Time frame: Up to 10 weeks
Assessment of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes
Blood samples for hematology assessment were collected for basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocytes. NA indicate data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)
Assessment of Hematology Parameters: Hematocrit and Reticulocytes/Erythrocytes (R/E)
Blood samples for hematology assessment were collected for Hematocrit and R/E. NA indicate data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)
Assessment of Hematology Parameter: Hemoglobin
Blood samples for hematology assessment was collected for Hemoglobin. NA indicate data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)
Assessment of Hematology Parameter: Eryrocyte Mean Corpuscular Hemoglobin
Blood samples for hematology assessment was collected for Eryrocyte Mean Corpuscular Hemoglobin. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)
Assessment of Hematology Parameter: Erythrocye Mean Corpuscular Volume
Blood samples for hematology assessment was collected for Erythrocyte Mean Corpuscular Volume. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)
Assessment of Hematology Parameters: Erythrocytes and Reticulocytes
Blood samples for hematology assessment were collected for Erythrocytes and reticulocytes. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)
Assessment of Hematology Parameters: Erythrocytes Distribution Width (EDW)
Blood samples for hematology assessment was collected for EDW. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)
Assessment of Clinical Chemistry Parameters: Albumin and Protein
Samples for clinical chemistry assessment were collected for Albumin and Protein. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)
Assessment of Clinical Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Creatine Kinase (CK) and Gamma Glutamyl Transferase (GGT)
Samples for clinical chemistry assessment were collected for ALP, AST, ALT, CK and GGT. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)
Assessment of Clinical Chemistry Parameters: Direct Bilirubin (DB), Bilirubin and Creatinine
Samples for clinical chemistry assessment were collected for DB, bilirubin and creatinine. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)
Assessment of Clinical Chemistry Parameters: Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Sodium and Urea
Samples for clinical chemistry assessment were collected for Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Sodium and Urea. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)
Number of Participants With Abnormal Urinalysis Result
Samples for urinalysis assessment was collected at Day -1, Day 13, Day 21, Day 27 and during follow-up period (10 to 14 daya after last dose). Data for participants with abnormal urinalysis results has been presented.
Time frame: Day -1, Day 13, Day 21, Day 27 and follow-up (10 to 14 days after last dose)
Number of Participants With Abnormal Electrocardiogram (ECG) Findings
ECG measurements was performed with the participant in a semi-supine position having rested in this position for at least 10 minutes beforehand. Data has been presented for Period 1, Day 14 pre-dose which showed abnormal- not clinically significant ECG finding. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Day 1, 14, 21, 28 and follow-up (10 to 14 days after last dose)
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Vital signs measurement was done in semi-supine position after 10 minutes rest and included SBP and DBP. Two blood pressure measurement were taken at pre-dose on Day 1, at least 1 minute apart. The mean value recorded at pre-dose was classified as Baseline. Single blood pressure was obtained at all other time points during the study. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Baseline to follow-up (10 to 14 days after last dose)
Change From Baseline in Pulse Rate
Vital signs measurement was done in semi-supine position after 10 minutes rest and included pulse rate. Two pulse rate measurement were taken at pre-dose on Day 1, at least 1 minute apart. The mean value recorded at pre-dose was classified as Baseline. Single pulse rate was obtained at all other time points during the study. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
Time frame: Baseline to follow-up (10 to 14 days after last dose)
A total of 15 participants were enrolled from one center in the United Kingdom. The study was conducted from 06 June 2017 to 07 September 2017.
| Milestone | CAB 30 mg Followed by RBT 300 mg + CAB 30 mg |
|---|---|
| Started | 15 |
| Completed | 14 |
| Not completed | 1 |
| Withdrew: Protocol-defined stopping criteria | 1 |
| Milestone | CAB 30 mg Followed by RBT 300 mg + CAB 30 mg |
|---|---|
| Started | 14 |
| Completed | 12 |
| Not completed | 2 |
| Withdrew: Adverse event | 2 |
Blood samples for PK analysis of CAB were collected at pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28. AUC (0 to tau) was calculated using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid. PK Summary Population included participants who had CAB PK parameter estimates from both serial PK sampling time periods 1 and 2. Comparisons were made for the repeated dose PK parameters of CAB when given alone in Period 1 and when co-administered with steady-state RBT in Period 2.
| Microgram * hour per milliliter | CAB 30 mg | RBT 300 mg + CAB 30 mg |
|---|---|---|
| Assessment of Plasma CAB Pharmacokinetic (PK) Parameter: Area Under the Concentration-time Curve Over One Dosing Interval (AUC [0 to Tau]) | 103.978 ± 28.3 | 81.715 ± 29.9 |
Blood samples for PK analysis of CAB were collected at pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28. Cmax was determined directly from the concentration-time data. Comparisons were made for the repeated dose PK parameters of CAB when given alone in Period 1 and when co-administered with steady-state RBT in Period 2.
| Micrograms per milliliter | CAB 30 mg | RBT 300 mg + CAB 30 mg |
|---|---|---|
| Assessment of Plasma CAB PK Parameter: Maximum Observed Concentration (Cmax) | 6.356 ± 24.7 | 5.246 ± 24.3 |
Blood samples for PK analysis of CAB were collected at pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28. Comparisons were made for the repeated dose PK parameters of CAB when given alone in Period 1 and when co-administered with steady-state RBT in Period 2.
| Micrograms per milliliter | CAB 30 mg | RBT 300 mg + CAB 30 mg |
|---|---|---|
| Assessment of Plasma CAB PK Parameter: Concentration at the End of the Dosing Interval (Ctau) | 3.359 ± 34.3 | 2.479 ± 36.3 |
Blood samples for PK analysis of CAB were collected at pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28. Tmax was determined directly from the concentration-time data.
| Hours | CAB 30 mg | RBT 300 mg + CAB 30 mg |
|---|---|---|
| Assessment of Plasma CAB PK Parameter: Time of Occurrence of Cmax (Tmax) | 3.000 (1.00 to 4.00) | 2.500 (1.00 to 4.00) |
Blood samples for PK analysis of CAB were collected at pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28. Apparent terminal half-life was calculated as: t1/2 = ln2 / Lambda_z, where Lambda_z is the terminal phase rate constant. Plasma t1/2 was not estimated for either period due to limited PK sampling in the terminal phase.
No measurements were reported for this outcome.
Blood samples for PK analysis of CAB were collected at pre-dose (within 15 minutes prior to dose) on Days 13 and 14; and 1, 2, 3, 4, 8, 12, and 24 hours post-dose on Day 14, pre-dose (within 15 minutes prior to dose) on Days 26, 27 and 28; and 1, 2, 3, 4, 8, 12 and 24 hours post-dose on Day 28. CL/F was calculated as CL/F =Dose/AUC(0 to tau).
| Liters per hour | CAB 30 mg | RBT 300 mg + CAB 30 mg |
|---|---|---|
| Assessment of Plasma CAB PK Parameter: The Apparent Oral Clearance (CL/F) | 0.289 ± 28.3 | 0.367 ± 29.9 |
An AE is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect and associated with liver injury and impaired liver function. Safety Population comprised of all participants who enrolled in the study and received at least one dose of study drug.
| Participants | CAB 30 mg | RBT 300 mg + CAB 30 mg |
|---|---|---|
| Any AEs | 1 | 7 |
| Any SAEs | 0 | 1 |
Concurrent medications included paracetamol and ibuprofen. Number of participants who took concurrent medications during the study are presented.
| Participants | CAB 30 mg | RBT 300 mg + CAB 30 mg |
|---|---|---|
| Paracetamol | 0 | 3 |
| Ibuprofen | 0 | 1 |
Blood samples for hematology assessment were collected for basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocytes. NA indicate data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| 10^9 cells/Liter | CAB 30 mg Followed by RBT 300 mg + CAB 30 mg |
|---|---|
| Basophils, Day -1, n=15 | 0.025 ± 0.0119 |
| Basophils, On-treatment, Period 1 Day 13, n=14 | 0.031 ± 0.0141 |
| Basophils, On-treatment, Period 2 Day 21, n=13 | 0.028 ± 0.0124 |
| Basophils, On-treatment, Period 2 Day 27, n=12 | 0.018 ± 0.0106 |
| Basophils, Follow-up, Period 1 Day 13, n=1 | 0.030 ± NA |
| Basophils, Follow-up, Period 2 Day 21, n=1 | 0.010 ± NA |
| Basophils, Follow-up, Period 2 Day 27, n=1 | 0.010 ± NA |
| Basophils, Follow-up, n=15 | 0.023 ± 0.0098 |
| Eosinophils, On-treatment, Day -1, n=15 | 0.259 ± 0.2001 |
| Eosinophils, On-treatment, Period 1 Day 13, n=14 | 0.285 ± 0.2264 |
| Eosinophils, On-treatment, Period 2 Day 21, n=13 | 0.315 ± 0.2306 |
| Eosinophils, On-treatment, Period 2 Day 27, n=12 | 0.219 ± 0.2815 |
| Eosinophils, Follow-up, Period 1 Day 13, n=1 | 0.370 ± NA |
| Eosinophils, Follow-up, Period 2 Day 21, n=1 | 0.010 ± NA |
| Eosinophils, Follow-up, Period 2 Day 27, n=1 | 0.120 ± NA |
| Eosinophils, Follow-up, n=15 | 0.273 ± 0.2621 |
| Lymphocytes, Day -1, n=15 | 2.509 ± 0.7383 |
| Lymphocytes, On-treatment, Period 1 Day 13, n=14 | 2.224 ± 0.6596 |
| Lymphocytes, On-treatment, Period 2 Day 21, n=13 | 2.071 ± 0.8625 |
| Lymphocytes, On-treatment, Period 2 Day 27, n=12 | 1.551 ± 0.6554 |
| Lymphocytes, Follow-up, Period 1 Day 13, n=1 | 1.200 ± NA |
| Lymphocytes, Follow-up, Period 2 Day 21, n=1 | 0.310 ± NA |
| Lymphocytes, Follow-up, Period 2 Day 27, n=1 | 0.480 ± NA |
| Lymphocytes, Follow-up, n=15 | 2.140 ± 0.7373 |
| Monocytes, Day -1, n=15 | 0.561 ± 0.1570 |
| Monocytes, On-treatment, Period 1 Day 13, n=14 | 0.548 ± 0.1397 |
| Monocytes, On-treatment, Period 2 Day 21, n=13 | 0.628 ± 0.1579 |
| Monocytes, On-treatment, Period 2 Day 27, n=12 | 0.488 ± 0.1442 |
| Monocytes, Follow-up, Period 1 Day 13, n=1 | 0.360 ± NA |
| Monocytes, Follow-up, Period 2 Day 21, n=1 | 0.480 ± NA |
| Monocytes, Follow-up, Period 2 Day 27, n=1 | 0.790 ± NA |
| Monocytes, Follow-up, n=15 | 0.545 ± 0.1503 |
| Neutrophils, Day -1, n=15 | 4.279 ± 1.2269 |
| Neutrophils, On-treatment, Period 1 Day 13, n=14 | 3.306 ± 0.9964 |
| Neutrophils, On-treatment, Period 2 Day 21, n=13 | 2.818 ± 1.0823 |
| Neutrophils, On-treatment, Period 2 Day 21, n=12 | 1.979 ± 0.6006 |
| Neutrophils, Follow-up, Period 1 Day 13, n=1 | 2.340 ± NA |
| Neutrophils, Follow-up, Period 2 Day 21, n=1 | 3.830 ± NA |
| Neutrophils, Follow-up, Period 2 Day 27, n=1 | 3.970 ± NA |
| Neutrophils, Follow-up, n=15 | 2.840 ± 0.8665 |
| Platelets, Day -1, n=15 | 234.7 ± 34.58 |
| Platelets, On-treatment, Period 1 Day 13, n=14 | 210.7 ± 31.46 |
| Platelets, On-treatment, Period 2 Day 21, n=13 | 214.5 ± 31.04 |
| Platelets, On-treatment, Period 2 Day 27, n=12 | 193.9 ± 34.47 |
| Platelets, Follow-up, Period 1 Day 13, n=1 | 206.0 ± NA |
| Platelets, Follow-up, Period 2 Day 21, n=1 | 206.0 ± NA |
| Platelets, Follow-up, Period 2 Day 27, n=1 | 169.0 ± NA |
| Platelets, Follow-up, n=15 | 229.8 ± 45.57 |
| Leukocytes, Day -1, n=15 | 7.633 ± 1.6572 |
| Leukocytes, On-treatment, Period 1 Day 13, n=14 | 6.394 ± 1.5268 |
| Leukocytes, On-treatment, Period 2 Day 21, n=13 | 5.859 ± 1.5835 |
| Leukocytes, On-treatment, Period 2 Day 27, n=12 | 4.256 ± 1.3035 |
| Leukocytes, Follow-up, Period 1 Day 13, n=1 | 4.300 ± NA |
| Leukocytes, Follow-up, Period 2 Day 21, n=1 | 4.640 ± NA |
| Leukocytes, Follow-up, Period 2 Day 27, n=1 | 5.370 ± NA |
| Leukocytes, Follow-up, n=15 | 5.822 ± 1.3583 |
Blood samples for hematology assessment were collected for Hematocrit and R/E. NA indicate data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Proportion of red blood cells in blood | CAB 30 mg Followed by RBT 300 mg + CAB 30 mg |
|---|---|
| Hematocrit, Day -1, n=15 | 0.411 ± 0.02107 |
| Hematocrit, On-treatment, Period 1 Day 13, n=14 | 0.427 ± 0.02432 |
| Hematocrit, On-treatment, Period 2 Day 21, n=13 | 0.415 ± 0.02277 |
| Hematocrit, On-treatment, Period 2 Day 27, n=12 | 0.425 ± 0.02139 |
| Hematocrit, Follow-up, Period 1 Day 13, n=1 | 0.413 ± NA |
| Hematocrit, Follow-up, Period 2 Day 21, n=1 | 0.419 ± NA |
| Hematocrit, Follow-up, Period 2 Day 27, n=1 | 0.412 ± NA |
| Hematocrit, Follow-up, n=15 | 0.411 ± 0.01766 |
| R/E, Day -1, n=15 | 0.008 ± 0.00228 |
| R/E, On-treatment, Period 1 Day 13, n=14 | 0.008 ± 0.00248 |
| R/E, On-treatment, Period 2 Day 21, n=13 | 0.008 ± 0.00209 |
| R/E, On-treatment, Period 2 Day 27, n=12 | 0.006 ± 0.00219 |
| R/E, Follow-up, Period 1 Day 13, n=1 | 0.013 ± NA |
| R/E, Follow-up, Period 2 Day 21, n=1 | 0.009 ± NA |
| R/E, Follow-up, Period 2 Day 27, n=1 | 0.003 ± NA |
| R/E, Follow-up, n=15 | 0.010 ± 0.00270 |
Blood samples for hematology assessment was collected for Hemoglobin. NA indicate data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Grams per Liter | CAB 30 mg Followed by RBT 300 mg + CAB 30 mg |
|---|---|
| Day -1, n=15 | 144.7 ± 7.25 |
| Period 1 Day 13, n=14 | 143.5 ± 7.51 |
| Period 2 Day 21, n=13 | 146.4 ± 8.13 |
| Period 2 Day 27, n=12 | 144.2 ± 9.93 |
| Follow-up, Period 1 Day 13, n=1 | 137.0 ± NA |
| Follow-up, Period 2 Day 21, n=1 | 147.0 ± NA |
| Follow-up, Period 2 Day 27, n=1 | 146.0 ± NA |
| Follow-up, n=15 | 140.1 ± 6.04 |
Blood samples for hematology assessment was collected for Eryrocyte Mean Corpuscular Hemoglobin. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Picograms | CAB 30 mg Followed by RBT 300 mg + CAB 30 mg |
|---|---|
| Day -1, n=15 | 29.77 ± 1.457 |
| On-treatment, Period 1 Day 13, n=14 | 29.54 ± 1.536 |
| On-treatment, Period 2 Day 21, n=13 | 30.13 ± 1.329 |
| On-treatment, Period 2 Day 27, n=12 | 29.74 ± 1.466 |
| Follow-up, Period 1 Day 13, n=1 | 29.30 ± NA |
| Follow-up, Period 2 Day 21, n=1 | 27.80 ± NA |
| Follow-up, Period 2 Day 27, n=1 | 30.90 ± NA |
| Follow-up, n=15 | 29.49 ± 1.451 |
Blood samples for hematology assessment was collected for Erythrocyte Mean Corpuscular Volume. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Femtoliters | CAB 30 mg Followed by RBT 300 mg + CAB 30 mg |
|---|---|
| Day -1, n=15 | 84.60 ± 3.522 |
| On-treatment, Period 1 Day 13, n=14 | 87.94 ± 2.829 |
| On-treatment, Period 2 Day 21, n=13 | 85.39 ± 3.367 |
| On-treatment, Period 2 Day 27, n=12 | 87.73 ± 3.997 |
| Follow-up, Period 1 Day 13, n=1 | 88.20 ± NA |
| Follow-up, Period 2 Day 21, n=1 | 79.20 ± NA |
| Follow-up, Period 2 Day 27, n=1 | 87.10 ± NA |
| Follow-up, n=15 | 86.59 ± 3.618 |
Blood samples for hematology assessment were collected for Erythrocytes and reticulocytes. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| 10^12 cells/Liter | CAB 30 mg Followed by RBT 300 mg + CAB 30 mg |
|---|---|
| Erythrocytes, Day -1, n=15 | 4.870 ± 0.3068 |
| Erythrocytes, On-treatment, Period 1 Day 13, n=14 | 4.869 ± 0.3400 |
| Erythrocytes, On-treatment, Period 2 Day 21, n=13 | 4.868 ± 0.3173 |
| Erythrocytes, On-treatment, Period 2 Day 27, n=12 | 4.855 ± 0.3605 |
| Erythrocytes, Follow-up, Period 1 Day 13, n=1 | 4.680 ± NA |
| Erythrocytes, Follow-up, Period 2 Day 21, n=1 | 5.290 ± NA |
| Erythrocytes, Follow-up, Period 2 Day 27, n=1 | 4.730 ± NA |
| Erythrocytes, Follow-up, n=15 | 4.761 ± 0.3372 |
| Reticulocytes, Day -1, n=15 | 0.043 ± 0.01246 |
| Reticulocytes, On-treatment, Period 1 Day 13, n=14 | 0.040 ± 0.01350 |
| Reticulocytes, On-treatment, Period 2 Day 21, n=13 | 0.040 ± 0.01097 |
| Reticulocytes, On-treatment, Period 2 Day 27, n=12 | 0.028 ± 0.00997 |
| Reticulocytes, Follow-up, Period 1 Day 13, n=1 | 0.064 ± NA |
| Reticulocytes, Follow-up, Period 2 Day 21, n=1 | 0.051 ± NA |
| Reticulocytes, Follow-up, Period 2 Day 27, n=1 | 0.014 ± NA |
| Reticulocytes, Follow-up, n=15 | 0.049 ± 0.01415 |
Blood samples for hematology assessment was collected for EDW. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Percentage of EDW | CAB 30 mg Followed by RBT 300 mg + CAB 30 mg |
|---|---|
| Day -1, n=15 | 12.91 ± 0.513 |
| On-treatment, Period 1 Day 13, n=14 | 13.13 ± 0.595 |
| On-treatment, Period 2 Day 21, n=13 | 12.89 ± 0.641 |
| On-treatment, Period 2 Day 27, n=12 | 12.90 ± 0.624 |
| Follow-up, Period 1 Day 13, n=1 | 13.40 ± NA |
| Follow-up, Period 2 Day 21, n=1 | 13.60 ± NA |
| Follow-up, Period 2 Day 27, n=1 | 12.40 ± NA |
| Follow-up, n=15 | 12.90 ± 0.535 |
Samples for clinical chemistry assessment were collected for Albumin and Protein. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Grams per Liter | CAB 30 mg Followed by RBT 300 mg + CAB 30 mg |
|---|---|
| Albumin, Day -1, n=15 | 45.2 ± 1.90 |
| Albumin, On-treatment, Period 1 Day 13, n=14 | 44.2 ± 2.58 |
| Albumin, On-treatment, Period 2 Day 21, n=13 | 43.4 ± 2.06 |
| Albumin, On-treatment, Period 2 Day 27, n=12 | 43.7 ± 1.87 |
| Albumin, Follow-up, Period 1 Day 13, n=1 | 38.0 ± NA |
| Albumin, Follow-up, Period 2 Day 21, n=1 | 44.0 ± NA |
| Albumin, Follow-up, Period 2 Day 27, n=1 | 42.0 ± NA |
| Albumin, Follow-up, n=15 | 42.7 ± 1.59 |
| Protein, Day -1, n=15 | 67.9 ± 3.98 |
| Protein, On-treatment, Period 1 Day 13, n=14 | 67.3 ± 3.22 |
| Protein, On-treatment, Period 2 Day 21, n=13 | 65.1 ± 3.82 |
| Protein, On-treatment, Period 2 Day 27, n=12 | 65.8 ± 4.00 |
| Protein, Follow-up, Period 1 Day 13, n=1 | 60.0 ± NA |
| Protein, Follow-up, Period 2 Day 21, n=1 | 63.0 ± NA |
| Protein, Follow-up, Period 2 Day 27, n=1 | 70.0 ± NA |
| Protein, Follow-up, n=15 | 63.7 ± 2.55 |
Samples for clinical chemistry assessment were collected for ALP, AST, ALT, CK and GGT. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| International units per Liter | CAB 30 mg Followed by RBT 300 mg + CAB 30 mg |
|---|---|
| ALP, Day -1, n=15 | 62.7 ± 14.52 |
| ALP, On-treatment, Period 1 Day 13, n=14 | 60.1 ± 14.34 |
| ALP, On-treatment, Period 2 Day 21, n=13 | 60.7 ± 13.94 |
| ALP, On-treatment, Period 2 Day 27, n=12 | 59.9 ± 17.83 |
| ALP, Follow-up, Period 1 Day 13, n=1 | 51.0 ± NA |
| ALP, Follow-up, Period 2 Day 21, n=1 | 61.0 ± NA |
| ALP, Follow-up, Period 2 Day 27, n=1 | 56.0 ± NA |
| ALP, Follow-up, n=15 | 60.7 ± 13.35 |
| ALT, Day -1, n=15 | 23.5 ± 7.07 |
| ALT, On-treatment, Period 1 Day 13, n=14 | 25.5 ± 8.83 |
| ALT, On-treatment, Period 2 Day 21, n=13 | 30.2 ± 20.12 |
| ALT, On-treatment, Period 2 Day 27, n=12 | 30.8 ± 29.65 |
| ALT, Follow-up, Period 1 Day 13, n=1 | 155.0 ± NA |
| ALT, Follow-up, Period 2 Day 21, n=1 | 39.0 ± NA |
| ALT, Follow-up, Period 2 Day 27, n=1 | 34.0 ± NA |
| ALT, Follow-up, n=15 | 37.3 ± 23.40 |
| AST, Day -1, n=15 | 18.5 ± 3.62 |
| AST, On-treatment, Period 1 Day 13, n=14 | 20.7 ± 6.85 |
| AST, On-treatment, Period 2 Day 21, n=13 | 20.9 ± 5.87 |
| AST, On-treatment, Period 2 Day 27, n=12 | 23.3 ± 11.48 |
| AST, Follow-up, Period 1 Day 13, n=1 | 83.0 ± NA |
| AST, Follow-up, Period 2 Day 21, n=1 | 26.0 ± NA |
| AST, Follow-up, Period 2 Day 27, n=1 | 37.0 ± NA |
| AST, Follow-up, n=15 | 24.9 ± 9.44 |
| CK, Day -1, n=15 | 133.6 ± 40.31 |
| CK, On-treatment, Period 1 Day 13, n=14 | 227.1 ± 303.97 |
| CK, On-treatment, Period 2 Day 21, n=13 | 104.2 ± 43.44 |
| CK, On-treatment, Period 2 Day 27, n=12 | 88.7 ± 42.09 |
| CK, Follow-up, Period 1 Day 13, n=1 | 1278.0 ± NA |
| CK, Follow-up, Period 2 Day 21, n=1 | 177.0 ± NA |
| CK, Follow-up, Period 2 Day 27, n=1 | 164.0 ± NA |
| CK, Follow-up, n=15 | 144.3 ± 80.81 |
| GGT, Day -1, n=15 | 25.5 ± 14.97 |
| GGT, On-treatment, Period 1 Day 13, n=14 | 22.6 ± 13.20 |
| GGT, On-treatment, Period 2 Day 21, n=13 | 26.8 ± 23.95 |
| GGT, On-treatment, Period 2 Day 27, n=12 | 28.1 ± 28.25 |
| GGT, Follow-up, Period 1 Day 13, n=1 | 17.0 ± NA |
| GGT, Follow-up, Period 2 Day 21, n=1 | 36.0 ± NA |
| GGT, Follow-up, Period 2 Day 27, n=1 | 82.0 ± NA |
| GGT, Follow-up, n=15 | 36.1 ± 33.77 |
Samples for clinical chemistry assessment were collected for DB, bilirubin and creatinine. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Micromoles per Liter | CAB 30 mg Followed by RBT 300 mg + CAB 30 mg |
|---|---|
| DB, Day -1, n=15 | 3.5 ± 2.00 |
| DB, On-treatment, Period 1 Day 13, n=14 | 3.5 ± 1.83 |
| DB, On-treatment, Period 2 Day 21, n=13 | 2.4 ± 1.45 |
| DB, On-treatment, Period 2 Day 27, n=12 | 2.2 ± 1.19 |
| DB, Follow-up, Period 1 Day 13, n=1 | 4.0 ± NA |
| DB, Follow-up, Period 2 Day 21, n=1 | 1.0 ± NA |
| DB, Follow-up, Period 2 Day 27, n=1 | 2.0 ± NA |
| DB, Follow-up, n=15 | 2.9 ± 1.39 |
| Bilirubin, Day -1, n=15 | 9.8 ± 6.72 |
| Bilirubin, On-treatment, Period 1 Day 13, n=14 | 10.1 ± 5.83 |
| Bilirubin, On-treatment, Period 2 Day 21, n=13 | 6.6 ± 4.74 |
| Bilirubin, On-treatment, Period 2 Day 27, n=12 | 5.3 ± 2.99 |
| Bilirubin, Follow-up, Period 1 Day 13, n=1 | 10.0 ± NA |
| Bilirubin, Follow-up, Period 2 Day 21, n=1 | 3.0 ± NA |
| Bilirubin, Follow-up, Period 2 Day 27, n=1 | 5.0 ± NA |
| Bilirubin, Follow-up, n=15 | 7.9 ± 3.83 |
| Creatinine, Day -1, n=15 | 83.1 ± 7.71 |
| Creatinine, On-treatment, Period 1 Day 13, n=14 | 85.9 ± 11.02 |
| Creatinine, On-treatment, Period 2 Day 21, n=13 | 88.4 ± 9.43 |
| Creatinine, On-treatment, Period 2 Day 27, n=12 | 83.8 ± 10.69 |
| Creatinine, Follow-up, Period 1 Day 13, n=1 | 64.0 ± NA |
| Creatinine, Follow-up, Period 2 Day 21, n=1 | 71.0 ± NA |
| Creatinine, Follow-up, Period 2 Day 27, n=1 | 91.0 ± NA |
| Creatinine, Follow-up, n=15 | 80.7 ± 9.65 |
Samples for clinical chemistry assessment were collected for Calcium, Chloride, Carbon Dioxide, Glucose, Potassium, Sodium and Urea. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Millimoles per Liter | CAB 30 mg Followed by RBT 300 mg + CAB 30 mg |
|---|---|
| Calcium, Day -1, n=15 | 2.31 ± 0.0539 |
| Calcium, On-treatment, Period 1 Day 13, n=14 | 2.34 ± 0.0770 |
| Calcium, On-treatment, Period 2 Day 21, n=13 | 2.29 ± 0.0720 |
| Calcium, On-treatment, Period 2 Day 27, n=12 | 2.28 ± 0.0844 |
| Calcium, Follow-up, Period 1 Day 13, n=1 | 2.27 ± NA |
| Calcium, Follow-up, Period 2 Day 21, n=1 | 2.38 ± NA |
| Calcium, Follow-up, Period 2 Day 27, n=1 | 2.06 ± NA |
| Calcium, Follow-up, n=15 | 2.28 ± 0.0400 |
| Chloride, Day -1, n=15 | 101.0 ± 1.73 |
| Chloride, On-treatment, Period 1 Day 13, n=14 | 100.5 ± 1.45 |
| Chloride, On-treatment, Period 2 Day 21, n=13 | 101.1 ± 2.40 |
| Chloride, On-treatment, Period 2 Day 27, n=12 | 101.8 ± 2.14 |
| Chloride, Follow-up, Period 1 Day 13, n=1 | 101.0 ± NA |
| Chloride, Follow-up, Period 2 Day 21, n=1 | 100.0 ± NA |
| Chloride, Follow-up, Period 2 Day 27, n=1 | 99.0 ± NA |
| Chloride, Follow-up, n=15 | 102.5 ± 2.07 |
| Carbon Dioxide, Day -1, n=15 | 25.6 ± 1.12 |
| Carbon Dioxide, On-treatment, Period 1 Day13, n=14 | 25.3 ± 1.38 |
| Carbon Dioxide, On-treatment, Period 2 Day21, n=13 | 27.4 ± 2.10 |
| Carbon Dioxide, On-treatment, Period 2 Day27, n=12 | 24.7 ± 3.11 |
| Carbon Dioxide, Follow-up, Period 1 Day 13, n=1 | 25.0 ± NA |
| Carbon Dioxide, Follow-up, Period 2 Day 21, n=1 | 27.0 ± NA |
| Carbon Dioxide, Follow-up, Period 2 Day 27, n=1 | 20.0 ± NA |
| Carbon Dioxide, Follow-up, n=15 | 25.7 ± 1.76 |
| Glucose, Day -1, n=15 | 5.27 ± 1.077 |
| Glucose, On-treatment, Period 1 Day 13, n=14 | 5.51 ± 0.487 |
| Glucose, On-treatment, Period 2 Day 21, n=13 | 5.45 ± 0.399 |
| Glucose, On-treatment, Period 2 Day 27, n=12 | 5.95 ± 1.103 |
| Glucose, Follow-up, Period 1 Day 13, n=1 | 5.00 ± NA |
| Glucose, Follow-up, Period 2 Day 21, n=1 | 5.40 ± NA |
| Glucose, Follow-up, Period 2 Day 27, n=1 | 6.00 ± NA |
| Glucose, Follow-up, n=15 | 5.35 ± 0.374 |
| Potassium, Day -1, n=15 | 4.22 ± 0.166 |
| Potassium, On-treatment, Period 1 Day 13, n=14 | 4.29 ± 0.250 |
| Potassium, On-treatment, Period 2 Day 21, n=13 | 4.36 ± 0.386 |
| Potassium, On-treatment, Period 2 Day 27, n=12 | 4.29 ± 0.247 |
| Potassium, Follow-up, Period 1 Day 13, n=1 | 3.90 ± NA |
| Potassium, Follow-up, Period 2 Day 21, n=1 | 4.00 ± NA |
| Potassium, Follow-up, Period 2 Day 27, n=1 | 4.10 ± NA |
| Potassium, Follow-up, n=15 | 4.31 ± 0.183 |
| Sodium, Day -1, n=15 | 141.1 ± 1.28 |
| Sodium, On-treatment, Period 1 Day 13, n=14 | 139.6 ± 1.82 |
| Sodium, On-treatment, Period 2 Day 21, n=13 | 140.3 ± 2.36 |
| Sodium, On-treatment, Period 2 Day 27, n=12 | 139.8 ± 2.09 |
| Sodium, Follow-up, Period 1 Day 13, n=1 | 139.0 ± NA |
| Sodium, Follow-up, Period 2 Day 21, n=1 | 140.0 ± NA |
| Sodium, Follow-up, Period 2 Day 27, n=1 | 137.0 ± NA |
| Sodium, Follow-up, n=15 | 141.1 ± 2.02 |
| Urea, Day -1, n=15 | 5.73 ± 1.4048 |
| Urea, On-treatment, Period 1 Day 13, n=14 | 5.19 ± 1.0830 |
| Urea, On-treatment, Period 2 Day 21, n=13 | 5.69 ± 1.3678 |
| Urea, On-treatment, Period 2 Day 27, n=12 | 5.18 ± 1.2104 |
| Urea, Follow-up, Period 1 Day 13, n=1 | 4.69 ± NA |
| Urea, Follow-up, Period 2 Day 21, n=1 | 2.79 ± NA |
| Urea, Follow-up, Period 2 Day 27, n=1 | 4.09 ± NA |
| Urea, Follow-up, n=15 | 5.34 ± 1.2189 |
Samples for urinalysis assessment was collected at Day -1, Day 13, Day 21, Day 27 and during follow-up period (10 to 14 daya after last dose). Data for participants with abnormal urinalysis results has been presented.
| Participants | CAB 30 mg | RBT 300 mg + CAB 30 mg |
|---|---|---|
| Number of Participants With Abnormal Urinalysis Result | 0 | 0 |
ECG measurements was performed with the participant in a semi-supine position having rested in this position for at least 10 minutes beforehand. Data has been presented for Period 1, Day 14 pre-dose which showed abnormal- not clinically significant ECG finding. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Participants | CAB 30 mg | RBT 300 mg + CAB 30 mg |
|---|---|---|
| Number of Participants With Abnormal Electrocardiogram (ECG) Findings | 1 | 0 |
Vital signs measurement was done in semi-supine position after 10 minutes rest and included SBP and DBP. Two blood pressure measurement were taken at pre-dose on Day 1, at least 1 minute apart. The mean value recorded at pre-dose was classified as Baseline. Single blood pressure was obtained at all other time points during the study. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Millimeters of Mercury | CAB 30 mg Followed by RBT 300 mg + CAB 30 mg |
|---|---|
| SBP, On-treatment, Period 1 Day 14, n=14 | -2.5 ± 9.17 |
| SBP, On-treatment, Period 2 Day 21, n=13 | 1.5 ± 11.90 |
| SBP, On-treatment, Period 2 Day 28, n=12 | 0.5 ± 8.74 |
| SBP, Follow-up, Period 2 Day 21, n=1 | 17.0 ± NA |
| SBP, Follow-up, n=15 | 3.7 ± 12.85 |
| DBP, On-treatment, Period 1 Day 14, n=14 | 0.8 ± 7.61 |
| DBP, On-treatment, Period 2 Day 21, n=13 | 2.0 ± 9.10 |
| DBP, On-treatment, Period 2 Day 28, n=12 | -1.6 ± 4.21 |
| DBP, Follow-up, Period 2 Day 21, n=1 | 9.5 ± NA |
| DBP, Follow-up, n=15 | 3.3 ± 9.04 |
Vital signs measurement was done in semi-supine position after 10 minutes rest and included pulse rate. Two pulse rate measurement were taken at pre-dose on Day 1, at least 1 minute apart. The mean value recorded at pre-dose was classified as Baseline. Single pulse rate was obtained at all other time points during the study. Change from Baseline was calculated by subtracting the post-dose value from the Baseline value. NA indicated data not available since only one participant was analyzed, therefore standard deviation was not derived. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Beats/minute | CAB 30 mg Followed by RBT 300 mg + CAB 30 mg |
|---|---|
| On-treatment, Period 1 Day 14, n=14 | -4.5 ± 8.31 |
| On-treatment, Period 2 Day 21, n=13 | -6.2 ± 9.98 |
| On-treatment, Period 2 Day 28, n=12 | 3.4 ± 9.52 |
| Follow-up, Period 2 Day 21, n=1 | 39.0 ± NA |
| Follow-up, n=15 | -1.3 ± 10.58 |
Collected over AEs and SAEs were collected from start of the study up to follow-up (up to 10 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CAB 30 mg | 0/15 (0%) | 0/15 (0%) | 1/15 (6.7%) |
| RBT 300 mg + CAB 30 mg | 0/14 (0%) | 1/14 (7.1%) | 7/14 (50%) |
| Event | CAB 30 mg | RBT 300 mg + CAB 30 mg |
|---|---|---|
| Alanine aminotransferase increasedInvestigations | 0/15 | 1/14 |
| Event | CAB 30 mg | RBT 300 mg + CAB 30 mg |
|---|---|---|
| LeukopeniaBlood and lymphatic system disorders | 0/15 | 1/14 |
| NeutropeniaBlood and lymphatic system disorders | 0/15 | 1/14 |
| PyrexiaGeneral disorders | 0/15 | 1/14 |
| Viral infectionInfections and infestations | 0/15 | 1/14 |
| Skin abrasionInjury, poisoning and procedural complications | 0/15 | 1/14 |
| Body temperature increasedInvestigations | 0/15 | 1/14 |
| Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders | 0/15 | 1/14 |
| HeadacheNervous system disorders | 0/15 | 1/14 |
| HyperkeratosisSkin and subcutaneous tissue disorders | 0/15 | 1/14 |
| ContusionInjury, poisoning and procedural complications | 1/15 | 0/14 |
| Age, Continuous(Years) | CAB 30 mg Followed by RBT 300 mg + CAB 30 mg |
|---|---|
| Mean | 43.7 ± 10.51 |
| Sex: Female, Male(Participants) | CAB 30 mg Followed by RBT 300 mg + CAB 30 mg |
|---|---|
| Female | 0 |
| Male | 15 |
| Race/Ethnicity, Customized(Participants) | CAB 30 mg Followed by RBT 300 mg + CAB 30 mg |
|---|---|
| Asian - Central/South Asian Heritage | 1 |
| White - White/Caucasian/European | 14 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Jun 2017 to primary completion in Sep 2017, 3 months.
Results were first posted in Feb 2019, 1 year 4 months after primary completion.
Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 3 months is below that.
Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cabotegravir · Rifabutin